CN100334094C - 抗肿瘤类似物 - Google Patents

抗肿瘤类似物 Download PDF

Info

Publication number
CN100334094C
CN100334094C CNB028196511A CN02819651A CN100334094C CN 100334094 C CN100334094 C CN 100334094C CN B028196511 A CNB028196511 A CN B028196511A CN 02819651 A CN02819651 A CN 02819651A CN 100334094 C CN100334094 C CN 100334094C
Authority
CN
China
Prior art keywords
compound
tgi
alkyl
cdcl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028196511A
Other languages
English (en)
Chinese (zh)
Other versions
CN1564822A (zh
Inventor
V·马蒂内滋
P·加勒戈
C·堀瓦斯
S·蒙特
I·曼扎纳雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9919954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100334094(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CN1564822A publication Critical patent/CN1564822A/zh
Application granted granted Critical
Publication of CN100334094C publication Critical patent/CN100334094C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNB028196511A 2001-08-07 2002-08-06 抗肿瘤类似物 Expired - Lifetime CN100334094C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0119243.4 2001-08-07
GBGB0119243.4A GB0119243D0 (en) 2001-08-07 2001-08-07 Antitumoral analogs of ET-743

Publications (2)

Publication Number Publication Date
CN1564822A CN1564822A (zh) 2005-01-12
CN100334094C true CN100334094C (zh) 2007-08-29

Family

ID=9919954

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028196511A Expired - Lifetime CN100334094C (zh) 2001-08-07 2002-08-06 抗肿瘤类似物

Country Status (22)

Country Link
US (1) US7763615B2 (https=)
EP (3) EP1414828B9 (https=)
JP (2) JP4684552B2 (https=)
KR (1) KR20040032150A (https=)
CN (1) CN100334094C (https=)
AT (1) ATE374777T1 (https=)
AU (1) AU2002313540B2 (https=)
CA (1) CA2455768C (https=)
CY (1) CY1107830T1 (https=)
DE (1) DE60222775T2 (https=)
DK (1) DK1414828T3 (https=)
ES (1) ES2294151T3 (https=)
GB (1) GB0119243D0 (https=)
HU (1) HU229779B1 (https=)
IL (2) IL160051A0 (https=)
MX (1) MXPA04001240A (https=)
NO (1) NO337476B1 (https=)
NZ (1) NZ530837A (https=)
PL (1) PL218295B1 (https=)
PT (1) PT1414828E (https=)
RU (1) RU2283842C2 (https=)
WO (1) WO2003014127A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN107033164A (zh) * 2010-05-25 2017-08-11 法马马有限公司 制备海鞘素化合物的合成方法
ME02395B (me) * 2010-11-12 2016-09-20 Pharma Mar Sa Kombinovana terapija sa antitumorskim alkaloidima
RU2562432C2 (ru) 2010-11-26 2015-09-10 Нек Корпорейшн Устройство видеокодирования, устройство видеодекодирования, способ видеокодирования, способ видеодекодирования и программа
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
HRP20231233T1 (hr) 2017-04-27 2024-01-19 Pharma Mar, S.A. Antitumorski spojevi
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
TW202116783A (zh) 2019-09-03 2021-05-01 西班牙商瑪製藥股份有限公司 盧比克替定治療惡性間皮瘤
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2023503318A (ja) * 2019-11-21 2023-01-27 ファルマ、マール、ソシエダード、アノニマ ルルビネクテジン製剤で小細胞肺がんを処置する方法
WO2021228414A1 (en) 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
KR20230004714A (ko) 2020-04-21 2023-01-06 파르마 마르, 에스.에이. 약물 항체 접합체
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2022048775A1 (en) 2020-09-04 2022-03-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2022101255A1 (en) 2020-11-10 2022-05-19 Pharma Mar, S.A. Lurbinectedin and irinotecan combinations
IN202141039393A (https=) * 2021-08-31 2023-03-03
US20240415834A1 (en) 2021-11-08 2024-12-19 Pharma Mar, S.A. Lurbinectedin and atezolizumab combinations
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
CN115304619A (zh) * 2022-04-08 2022-11-08 上海皓元医药股份有限公司 一种卢比替定的晶型及其制备方法
CN114940682A (zh) * 2022-05-18 2022-08-26 博瑞制药(苏州)有限公司 芦比替定的晶型及其制备方法和用途
WO2024186263A1 (en) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
WO2024188978A1 (en) 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
WO2025059336A1 (en) * 2023-09-13 2025-03-20 Navinta, Llc An improved process for preparation of lurbinectedin
WO2025077996A1 (en) 2023-10-09 2025-04-17 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP4563149A1 (en) 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2026022359A2 (en) 2024-07-26 2026-01-29 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009607A1 (en) * 1990-11-30 1992-06-11 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO2000018233A1 (en) * 1998-09-30 2000-04-06 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
WO2000069862A2 (en) * 1999-05-14 2000-11-23 Pharma Mar, S.A. Hemisynthetic method and intermediates thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
CN1157189C (zh) 1998-04-06 2004-07-14 伊利诺伊大学评议会 半合成海鞘素
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
JP2003520801A (ja) * 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
JP5219323B2 (ja) * 2000-04-12 2013-06-26 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009607A1 (en) * 1990-11-30 1992-06-11 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO2000018233A1 (en) * 1998-09-30 2000-04-06 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
WO2000069862A2 (en) * 1999-05-14 2000-11-23 Pharma Mar, S.A. Hemisynthetic method and intermediates thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168075A1 (zh) * 2024-02-08 2025-08-14 映恩生物科技(上海)有限公司 海鞘素类化合物及其应用

Also Published As

Publication number Publication date
IL160051A (en) 2012-01-31
JP2011026331A (ja) 2011-02-10
HUP0401174A3 (en) 2005-12-28
CN1564822A (zh) 2005-01-12
EP2270018A1 (en) 2011-01-05
EP1414828B9 (en) 2008-02-20
PL367940A1 (en) 2005-03-07
US7763615B2 (en) 2010-07-27
JP4684552B2 (ja) 2011-05-18
DK1414828T3 (da) 2008-02-04
AU2002313540B2 (en) 2008-05-22
CA2455768C (en) 2011-10-11
WO2003014127A1 (en) 2003-02-20
RU2283842C2 (ru) 2006-09-20
ATE374777T1 (de) 2007-10-15
DE60222775T2 (de) 2008-07-17
NO20040961L (no) 2004-03-05
GB0119243D0 (en) 2001-10-03
NZ530837A (en) 2005-07-29
HUP0401174A2 (hu) 2005-09-28
DE60222775D1 (de) 2007-11-15
EP1806349A1 (en) 2007-07-11
CA2455768A1 (en) 2003-02-20
US20060128711A1 (en) 2006-06-15
CY1107830T1 (el) 2013-06-19
PT1414828E (pt) 2007-12-27
KR20040032150A (ko) 2004-04-14
HK1065786A1 (en) 2005-03-04
ES2294151T3 (es) 2008-04-01
RU2004106617A (ru) 2005-04-10
PL218295B1 (pl) 2014-11-28
MXPA04001240A (es) 2004-06-03
IL160051A0 (en) 2004-06-20
EP1414828B1 (en) 2007-10-03
NO337476B1 (no) 2016-04-18
HU229779B1 (en) 2014-07-28
JP2005501093A (ja) 2005-01-13
EP1414828A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
CN100334094C (zh) 抗肿瘤类似物
AU2002313540A1 (en) Antitumoral analogs
US8076337B2 (en) Antitumoral derivatives of ET-743
EP2305689B1 (en) The synthesis of naturally occuring ecteinascidins and related compounds
AU2002317967A1 (en) New antitumoral derivatives of ET-743
HK1065786B (en) Antitumoral analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070829